Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis

dc.contributor.authorLucientes Continente, Laura
dc.contributor.authorFernández Juárez, Gema
dc.contributor.authorMárquez Tirado, Bárbara
dc.contributor.authorJiménez Villegas, Laura
dc.contributor.authorAcevedo, Mercedes
dc.contributor.authorCavero, Teresa
dc.contributor.authorCámara, Luís Sánchez
dc.contributor.authorDraibe, Juliana
dc.contributor.authorAnton Pampols, Paula
dc.contributor.authorCaravaca Fontán, Fernando
dc.contributor.authorPraga, Manuel
dc.contributor.authorVillacorta, Javier
dc.contributor.authorGoicoechea de Jorge, Elena
dc.date.accessioned2024-02-26T14:27:37Z
dc.date.available2024-02-26T14:27:37Z
dc.date.issued2024-01-01
dc.date.updated2024-02-26T13:23:10Z
dc.description.abstractActivation of the alternative pathway (AP) of complement is involved in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), although the underlying molecular mechanisms are unclear. To gain insight into the role of the AP, common gene variants in CFH/CFHR1-5, CFB, C3 and MCP, and longitudinal determinations of plasma C3, C4, FH, FHR-1, FHR-2, FHR-5, FB, properdin and sC5b-9 levels were analyzed in a Spanish AAV cohort consisting of 102 patients; 54 with active AAV (active cohort) and 48 in remission not receiving immunosuppressants or dialysis therapy (remission cohort). The validation cohort consisted of 100 patients with ANCA-associated glomerulonephritis. Here, we demonstrated that common genetic variants in complement components of the AP are associated with disease susceptibility (CFB32Q/W) or severity of kidney damage in AAV (CFH-H1, CFH1H2 and DCFHR3/1). Plasma levels of complement components were significantly different between active and remission cohorts. In longitudinal observations, a high degree of AP activation at diagnosis was associated with worse disease outcome, while high basal FHR-1 levels and lower FH/FHR-1 ratios determined severe forms of kidney associated AAV. These genetic and plasmatic findings were confirmed in the validation cohort. Additionally, autoantibodies against FH and C3 convertase were identified in one and five active patients, respectively. Thus, our study identified key genetic and plasma components of the AP that determine disease susceptibility, prognosis, and severity in AAV. Our data also suggests that balance between FH and FHR-1 is critical and supports FHR-1 as a novel AP -specific therapeutic target in AAV. Kidney International (2024) 105, 177-188; https://doi.org/10.1016/ j.kint.2023.10.013
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn0085-2538
dc.identifier.pmid37923132
dc.identifier.urihttps://hdl.handle.net/2445/208062
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.kint.2023.10.013
dc.relation.ispartofKidney International, 2024, vol. 105, num. 1, p. 177-188
dc.relation.urihttps://doi.org/10.1016/j.kint.2023.10.013
dc.rightscc by-nc-nd (c) Lucientes Continente, Laura et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationVasculitis
dc.subject.classificationImmunogenètica
dc.subject.otherVasculitis
dc.subject.otherImmunogenetics
dc.titleComplement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
PIIS0085253823007597.pdf
Mida:
1.86 MB
Format:
Adobe Portable Document Format